FOXO4-DRI vs NR
A side-by-side research comparison of FOXO4-DRI and NR across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | NR |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Nicotinamide Riboside |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Dietary compound (clinical studies) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Converted to NMN and then NAD+ via the salvage pathway (NRK enzymes). Higher NAD+ supports sirtuins, DNA repair, and mitochondrial energy production. |
| Molecular weight | ~4,500 Da | 255.25 Da |
| Half-life | 12-24 hours (D-amino acid stability) | Short; rapidly converted to NAD+ |
| Bioavailability | Moderate (SubQ) | Oral absorption well documented |
| Typical dose | 5-10 mg/kg (animal studies) | 250-1000 mg per day |
| Frequency | 3x per week for 3 weeks | Once daily |
| Route | Subcutaneous | Oral |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
NR reported benefits
- Raises NAD+ levels
- Supports mitochondrial energy
- Well-studied oral safety
- Studied for metabolic and cardiovascular health
Related comparisons
Research and educational reference only. Not medical advice.